Summary.-Cells from 3 human tumours have been grown in soft agar contained in Millipore diffusion chambers and implanted i.p. in mice. Clonal growth was obtained from fresh biopsy samples, from cryopreserved tissue, and from xenografts of the tissues in immune-suppressed mice. The radiosensitivities of a melanoma and an ovarian carcinoma were evaluated by in vitro irradiation before assay for colony formation. Xenografting did not modify the radiosensitivity of the melanoma. Cells from another tumour were exposed to Adriamycin or cyclophosphamide whilst contained within i.p. diffusion chambers; the sensitivity was similar for cryopreserved and xenografted cells. The results encourage further attempts to quantify the sensitivity of human tumour cells by these methods.
THE DIRECT MEASUREMENT of the sensitivity of human tumour cells to drugs and radiation is an important objective. Extensive studies of clonogenic cell survival have been made in experimental tumours, but studies on human cells have been limited largely by lack of the necessary assay techniques. Recent work in this laboratory has produced 3 clonogenic assays that are applicable to human tumour cells: an in vitro replenishable softagar assay  Courtenay , ain i.p. agar diffusion chamber (ADC) assay (S*mith et al., 1976) and a lung colony assAy in immune-deprived mice (Thomas, 1979; Selby & Thomas, 1980) . These have mostly been applied in examining the chemosensitivity and radiosensitivity of xenografted human tumours, but clonal growth of cells taken from patients has also been obtained . The present paper describes our first attempts to use the ADC assay to determine cellsurvival curves after drug treatment or irradiation of human cells that have not been xenografted.
Alternative in vitro clonogenic assays have been described by Hamburger & Salmon (1977) . These have been used to estimate the sensitivity of clonogenic human tumour cells to drug therapy in vitro, and encouraging correlations with clinical responses are reported (Salmon et al., 1978; Alberts et al., 1980) . Their studies were limited to single experiments, and plating efficiencies (PE) were often low. The present study was restricted to samples with PEs of more than about 10% and cryopreservation allowed repeated experiments and an assessment of the reproducibility of results.
There is now some evidence that xenografted human tumours may retain the chemosensitivity of their original tumour (Giovanella et at., 1978; Shorthouse et at., 1980 measurement of cell survival in the original tumour with those in the early-passage xenografts, which provides an alternative approach to this question.
MATERIALS AND METHODS
Tumours and cryopreservation.-Tumour samples from 3 patients were used in this study (Table I ). The 2 solid tumours were immersed in Ham's F12 medium at 4°C immediately after removal, and transported to the laboratory. They were washed in medium, dissected free of necrotic material, and cut into 2mm cubes. S.c. implants of the cubes were made bilaterally into 5 CBA/lac mice, immune-suppressed by thymectomy, cytosine arabinoside pretreatment and 9 Gy whole-body irradiation Selby et al., 1980 .
Colony analysis.-Colonies were studied by histology, immunofluorescence and electron microscopy, using techniques previously described (Selby et al., 1980a) .
RESULTS
Colony growth was assayed for each of the tumour samples at the time of biopsy, after cryopreservation and, in the case of HX47 and HX49, after growth as xenografts for up to 5 passages. The PEs are shown in Table II in Ham's F12 medium for 12 h before irradiation (Fig. 1 ). those from the xenograft, the difference is not statistically significant. On the basis of the few data points obtained for Adriamycin, the xenograft and cryopreserved cells were similarly sensitive.
DISCUSSION
In a moderately extensive study of more than 40 human tumour biopsy samples, a high proportion were found to form colonies in soft agar (Courtenay et al., 1978, and unpublished) . However, only 3 samples were obtained which yielded adequate numbers of viable cells in suspension, grew in the ADC assay with PE >10,% and were available in sufficient quantities to allow direct cloning, cryopreservation, xenografting and reproducible cell survival studies. The data in the present report appears that the ADC systemn provides a means of studying clonogenic cell survival in human tumours without prior adaptation to growth in experimental conditions. Cryopreservation did not reduce the PE of the tumours, and it allowed an assessment of the reproducibility of results. In an earlier study melanoma xenografts that had been reestablished after cryopreservation were found not to have changed their chemosensitivity to 3 different drugs.
The shapes of the dose-response curves after in vitro irradiation of cryopreserved human tumour cells were of the typical shoulder-exponential type described for mammalian cells. The parameters of the curves are within the range found for experimental animal tumours, human cell lines and human tumour xenografts (Hall, 1978; Smith et al., 1978; Guichard et al., 1977) . Radiation dose-response curves have not previously been reported for human tumour cells without an intermediate stage of tissue culture or growth as xenografts. The exponential curve for cyclophosphamide is also compatible with studies using this drug to treat animal tumours, cell lines and human tumour xenografts (Smith et al., 1976; Hill & Stanley, 1979; van Putten & Lelieveld, 1970) . There were insufficient data for Adriamycin to allow conclusions about the shape of the dose-response curve.
The similarity between the responses of cryopreserved cells and xenografted cells to irradiation, cyclophosphamide and Adriamycin supports the hypothesis that xenografting does not substantially alter the inherent sensitivity of tumour cells to treatment, at least in early passages. Cryopreservation has important technical advantages when dealing with cells that have a low and unpredictable PE. As used here it allows the drug sensitivity of tumours to be compared with their xenografts using the same endpoints for each, and with the same activation and metabolism of the drug under test. As a way of evaluating xenografts it may be complementary to the conventional approach of comparing xenograft responses measured by tumour-volume changes with clinical responses in the patient.
The ADC system for the treatment of cells with drugs is highly artificial, in particular because ofthe isolation oftreated cells from each other and the absence of a tumour stroma. However, we have found with a number of melanoma xenografts that the sensitivity to melphalan, methyl-CCNU, DTIC and Adriamycin was often the same whether the cells were exposed as a xenograft or in the ADC system; in a few cases the ADC-exposed cells were more sensitive, as found by Smith & Gordon (1978) . The advantages of ADC exposure over alternative in vitro methods for the treatment of human tumour cells are that it allows for in vivo drug activation and the in vivo pharmacokinetics ofthe drugs under test. Studies in our own laboratory (Bateman et al., 1980) and others (Ogawa et al., 1973) support the suggestion that in vitro drug testing can predict in vivo tumour responses in animal tumours and human tumour xenografts, but these have been restricted to drugs that are not thought to require in vivo activation.
The PE of tumours in this study and in those of other groups are low, which suggests the possibility that atypical subpopulations of cells are being grown and treated, leading to erroneous estimates of the sensitivity of the whole tumour (Hamburger & Salmon, 1977; . This possibility is reduced by the similarity of the results for xenografted tumours which had higher PEs, and also by the observation that results were similar for xenograft tumours when colonies were grown under widely differing conditions in a lung colony assay (Selby & Thomas, 1980) . The ADC system is expensive and labour-intensive when compared to in vitro cloning assays. Xenografting and cryopreservation of tumours and examination only of those with PE > 1% places limits upon the number of tumours which may be studied. However, the combination of these approaches with the simpler, more direct methods which are being developed, may lead to reliable estimation of the sensitivities of clonogenic tumour cells to cytotoxic treatments.
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